Vaderis is a clinical stage biotechnology company focussed on the treatment of rare diseases caused by Vascular Malformations.
Location: Switzerland
Total raised: $152M
Investors 2
| Date | Name | Website |
| 08.09.2026 | Omega Fund... | omegafunds... |
| - | Droia Onco... | droiaventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2026 | Series B | $152M | Omega Fund... |
Mentions in press and media 15
| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 12.08.2026 | Vaderis Therapeutics Raises $152 Million Series B And Launches Phase 3 HEROIC Study For Engasertib | Vaderis Therapeutics has closed an oversubscribed $152 million Series B financing and initiated its global Phase 3 HEROIC study evaluating engasertib in patients with hereditary hemorrhagic telangiectasia. The private financing was co-led b... |
| 11.08.2026 | ‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder | Vaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rare blood vessel disorder to market. The Base... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing Tue, Aug 11, 2026 13:00 CET Report this content EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 11.08.2026 | Paradigm HSE Receives Investment From Quad-C Management | Paradigm HSE, a Houston, Texas-based provider of health and safety solutions, received an investment from Quad-C Management. The amount of the deal was not disclosed. The company intends to use the funds to accelerate growth both organicall... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding. The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing | Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 11.08.2026 | Venture Capital & Startup Funding Roundup, August 11, 2026: Bessemer Venture Partners, Citi, Sequoia Capital, Thiel Capital & More | The big picture from today’s activity: investors are pouring money into industry-specific AI and hardware-infused sectors. We see a surge of capital into defense and aerospace startups (for example, drone-maker Neros and air-taxi maker Vert... |
| 11.08.2026 | Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia | - |
| 03.12.2025 | Four biotech startups reach key milestones | MUVON Therapeutics AG, which is focused on the treatment of stress urinary incontinence (SUI) in women, has achieved positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle... |
Show more